ArticleScientific reports2025
Next generation antimicrobial peptide disinfectant targeting biocide and vancomycin resistant staphylococcus aureus through integrated in Silico and in vitro validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antimicrobial Peptides, Bacteriocins and Mycocins as Natural Antimicrobials: Applications in Food Safety, Agriculture and Healthcare.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Peptides as Next-Generation Disinfectants: Tackling Biocide and Antimicrobial Resistance in Hospital Hygiene - A Narrative Review.Probiotics and antimicrobial proteins · 2026Review
- Article
- Unveiling the spectrum of vancomycin resistance in Staphylococcus aureus from Hospital-acquired urinary tract infections (HA-UTI) in cardiac patients.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of biocide- and antibiotic-resistant microbes in hospital settings demands urgent and innovative strategies to curb the spread of antimicrobial resistance (AMR). This study presents an innovative disinfectant strategy that leverages antimicrobial peptides (APep) extracted from antimicrobial-producing (AMP) strains isolated from hospital environments under intense antibiotic pressure. Unlike traditional probiotic disinfectants that rely on live bacterial strains prone to AMR, this approach directly utilizes APep from non-resistant strains with a high antioxidant potential to combat AMR and oxidative stress. Candidate strains were selected based on antimicrobial susceptibility profiling, oxidative stress assays, and screening for antimicrobial activity against hospital-acquired pathogens. The active compounds were characterized using fourier-transform infrared (FTIR) spectroscopy, high-performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and whole-genome sequencing. Biosynthetic pathways were explored using in silico analyses, including biosynthetic gene clusters (BGCs) mapping, APep prediction, and gene interaction network analyses. Bacillus paralicheniformis UAB33 was identified as a potent producer of bacitracin B1 (UB1), exhibiting strong activity against biocides and vancomycin-resistant Staphylococcus aureus (VRSA). Genomic analysis revealed 14 BGCs, including key non-ribosomal peptides (NRPs) such as bacitracin, lichenysin, and bacillibactin. A unique pathway involving bacA, bacB, and bacC genes, along with adjacent post-translationally modified peptides (RiPP) clusters, was elucidated to enhance bacitracin synthesis. UB1-infused disinfectant wipes significantly reduce microbial loads on hospital surfaces in vitro, demonstrating a promising strategy for mitigating resistant pathogens. This strategy presents a promising approach for curbing the spread of antibiotic resistance in healthcare settings and offers a scalable and innovative solution for infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.